Results showed that IL10-MSCs could significantly counteract the HFD-induced obesity-related metabolic symptoms including body weight gain, hepatic and adipocyte lipids accumulation, glucose tolerance, insulin resistance, and serum lipid indicators, compared with unmodified MSCs. Here, IL10 is linked to obesity due to melanocortin 4 receptor deficiency.